Communication To Health Care Professionals Archives - Page 2 of 9

09 Apr Pseudoephedrine-containing Medicines Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS) – J&J

Posted at 09:03h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Johnson and Johnson (Pty) Ltd would like to inform you about the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with the use of pseudoephedrine-containing medicines....

31 Mar Topiramate – Risk of Neurodevelopmental Disorders

Posted at 15:34h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Ranbaxy Pharmaceuticals (Pty) Ltd South Africa, Zydus Healthcare SA (Pty) Ltd and, Trinity Pharma (Pty) Ltd wish to inform you about the risk of neurodevelopmental disorders in the children born to women exposed to...

27 Feb The Risk of Meningioma Associated With the Use of Medroxyprogesterone Acetate

Posted at 08:39h in

Pfizer and Viatris Healthcare South Africa (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the increased risk of meningioma associated with prolonged use....

23 Sep DHCPL – Tegretol S 100 mg Per 5 ml Carbamazepine Suspension

Posted at 11:33h in

Novartis, during its portfolio review (Tegretol S® oral suspension included) observed the possibility of exceeding defined permitted daily exposure (PDE) when the product is taken above 1200 mg/day in adult patients because of the quantity of sorbitol in the formulation. Sorbitol is one of the...

03 Sep DHCPL – Pseudoephedrine-Containing Medicines Risks of PRES and RCVS – iNova Pharmaceuticals

Posted at 07:40h in

The DHCP letter is intended to inform healthcare professionals about the risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with the use of pseudoephedrine-containing medicines. Pseudoephedrine-containing medicines are contraindicated in patients with severe or uncontrolled hypertension, or with severe acute or...

03 Sep DHCPL – Pseudoephedrine-Containing Medicines Risks of PRES and RCVS – Adcock and other Collaborators

Posted at 07:32h in

08 Jul GSK DHCPL – Risk of DRESS associated with use of aciclovir and valaciclovir-containing medicines

Posted at 13:29h in

GlaxoSmithKline (GSK) South Africa, in collaboration with SAHPRA, would like to inform healthcare professionals about the risk of drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of aciclovir and valaciclovir-containing medicines....

06 Jul Recommended Calculations of Contraception Duration after Completion of Therapy with Genotoxic Anticancer Medicines – Dr Reddy’s Laboratories

Posted at 14:04h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Dr. Reddy’s Laboratories (Pty) Ltd would like to draw your attention to the recommended calculations of contraception duration after completion of therapy with genotoxic anticancer medicines (including potential genotoxic metabolites)....

02 Jul Recommended Calculation of Contraception Duration After Completion of Therapy to Minimise Risk of Embryotoxicity and Teratogenicity Associated With the Use of Halaven® (Eribulin Mesylate)

Posted at 18:10h in

Eisai Pharmaceuticals Africa (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about the recommended calculations of contraception duration after completion of therapy with Halaven® (eribulin mesylate), including its potential genotoxic metabolites....

27 Jun DHCPL – IV Tranexamic Acid Risk of Intrathecal Administration Error – PharmaDynamics and other collaborators

Posted at 08:31h in

PharmaDynamics and other collaborators, would like to warn healthcare professionals about the risk of intrathecal administration of intravenous (IV) tranexamic acid, which may result in serious lifethreatening injuries, including seizures, cardiac arrhythmias, paraplegia, permanent neurological injury, and death. There have been reports of IV tranexamic...

Archive